BRITISH COLUMBIA, Canada, Oct. 28 /CNW/ -- InNexus Biotechnology Inc.,
(OTC Bulletin Board: IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com), a drug
development company commercializing the next generation of monoclonal
antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announces
that Jeff Morhet, CEO and Chairman, will present at the 7th Annual BIO
Investor Forum on October 30, 2008.
Mr. Morhet's thirty-minute presentation to potential investors and
industry partners will begin at 3:15PM within the Twin Peaks South Room of the
Palace Hotel in San Francisco, California. He will provide a company
overview, including information about InNexus' unique business strategy, its
DXL(TM) technology platform, recent partnerships and company milestones.
The 7th Annual BIO Investor Forum will be held October 29-31, 2008 at the
Palace Hotel in San Francisco, California. The BIO Investor Forum is held
every year to bring late-stage private and emerging public biotech companies
and investors together to meet and attend roundtables, panel discussions and
seminars on a variety of biotechnology topics.
InNexus is a drug development company commercializing the next generation
of monoclonal antibodies based on its DXL(TM) technology, which improves the
potency of existing antibody products while opening new markets and disease
applications. DXL(TM) antibodies utilize unique, novel and patented methods
and technologies of InNexus.
InNexus is headquartered in British Columbia with principal management
based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own
in-house developmental facilities. These development resources provide
validation of protein and peptide discoveries, enabling InNexus (and its
strategic partners) to advance novel drug therapeutics and diagnostics. To
learn more about InNexus, please visit http://www.ixsbio.com.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this news release. This news
release may contain assumptions, estimates, and other forward-looking
statements that involve inherent risks and uncertainties and are subject to
factors, many of which are beyond the Company's control, that may cause actual
results or performance to differ materially from those currently anticipated
in such statements.
For further information:
For further information: Wade Brooksby, Chief Financial Officer of
InNexus Biotechnology Inc., +1-480-862-7500 Web Site: http://www.ixsbio.com